Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions [Yahoo! ...
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting new data on the results of the RP-A501 Phase 1 trial to treat patients with Danon disease at the American Heart Association's 2024 Late-Breaking Science sessions being held from November 16-18, 2024 in Chicago, Illinois. Details for the presentation are as follows: Title : Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy Session: Amyloid, Hypertrophic and Danon Cardiomyopathies: Targeted Therapies and Specific Populations Presenter : Joseph Rossano, M.D., M.S., FAAP, FACC, Co-Director of the Cardiac Center and Chief of the Division of Cardiology at Children's Hospital of Philadelphia Date and Time : Monday, November 18, 2024, from 9:45-9:57 a.m. CT Rocket plans to host an investor webinar on November 18, 2024
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.MarketBeat
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.MarketBeat
RCKT
Earnings
- 11/7/24 - Beat
RCKT
Sec Filings
- 11/21/24 - Form 144
- 11/21/24 - Form 144
- 11/21/24 - Form 144
- RCKT's page on the SEC website